Hawryluk P. Kent

CEO Hawryluk buys 18,500 MBX shares at $28.41; 2 prior MBX buys both showed +90d returns; stock now -30.9% from 52-week high amid -$21.6M net income.

P. Kent Hawryluk, the CEO, purchased 18,500 shares at $28.41, bringing his holdings to 486,777 shares (+4.0% vs pre-transaction), on 2026-03-13. His prior trade history at MBX is notable: two earlier buys on 2025-10-20 and 2025-02-04 both delivered positive 90-day returns (+100.8% and +12.9% respectively), with both timed at the 90-day inflection point where the stock subsequently rose. His cross-ticker track record reinforces this pattern: 2 prior buys averaged +105.0% 90-day return with a 100.00% win rate. The current buy occurs as MBX trades -30.9% from its 52-week high of $43.14, and the company reported a -$21.6M net income over its most recent fiscal year. The buy's proximity to the 90-day inflection point that historically preceded price appreciation—combined with the company's unprofitable fundamentals and depressed price relative to recent highs—suggests this filing merits examination of whether the CEO's prior timing accuracy repeats.

MBX CEO Hawryluk buys 20,000 shares at $13.64, expanding stake to 468,277 shares amid unprofitable fundamentals

P. Kent Hawryluk, President & CEO of MBX Biosciences, purchased 20,000 shares for $272,790.00 on 2025-10-20, increasing his holdings by 4.5% to 468,277 shares. This buy occurs at $13.64 per share, approximately 11% below the current price of $15.31 and 43.6% below the 52-week high of $24.19, yet the stock has gained 53.1% over the past 30 days. Notably, the company reported a net loss of $19,411,000.00 for its most recent full fiscal year, placing this insider accumulation in the context of negative profitability. His single prior purchase at MBX in February 2025 exhibited similar characteristics, with a positive 90-day return of +12.9%, demonstrating a timing pattern where prior buys preceded positive returns at this ticker—a data point that captures recent momentum but does not offset the underlying operational losses.

MBX CEO Kent Hawryluk purchased 50,000 shares at $10.69; stock -56.7% from 52-week high, company posted $-18.1M net loss.

President & CEO Hawryluk purchased 50,000 shares at $10.69 on 2025-02-04, expanding his holdings from 398.3K to 448.3K shares (+12.6%). The purchase occurs in a deteriorating price environment: the stock trades -56.7% from its 52-week high of $25.98, down -30.9% over 30 days and -51.6% over 90 days. Concurrently, the company reported a net loss of $-18.1M, signaling operational challenges alongside the equity decline. The magnitude of this buy (50.0K shares for $534.5K) and the CEO's direct commitment of capital warrant investor scrutiny into whether the purchase reflects management confidence in recovery or occurs in isolation from broader business momentum.